Dopamine agonists in the treatment of Parkinson’s disease

References

• Hattori N, Mizuno Y. Pathogenetic mechanisms of parkin in Parkinson’s disease. Lancet 364(9435), 722–724 (2004).
   PubMed Web of Science ®Google Scholar
• Trojanowski JQ, Lee VM. Parkinson’s disease and related alpha-synucleinopathies are brain amyloidoses. Ann. N. Y. Acad. Sci. 991, 107–110 (2003).
   PubMed Web of Science ®Google Scholar
• Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res. 318(1), 121–134 (2004).
   PubMed Web of Science ®Google Scholar
• Calne DB. Treatment of Parkinson’s disease. N. Engl. J. Med.30(14), 1021–1027 (1993).
   Google Scholar
• Bennett JP Jr, Piercey MF. Pramipexole – a new dopamine agonist for the treatment of Parkinson’s disease. J. Neurol. Sci. 163(1), 25–31 (1999).
   PubMed Web of Science ®Google Scholar
• Tan EK, Jankovic J. Choosing dopamine agonists in Parkinson’s disease. Clin. Neuropharmacol. 24(5), 247–253 (2001).
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. (056 Study Group). N. Engl. J. Med.342(20), 1484–1491 (2000).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson’s disease: a randomized controlled trial. JAMA284(15), 1931–1938 (2000).
   PubMed Web of Science ®Google Scholar
• Bracco F, Battaglia A, Chouza C et al. PKDS009 Study Group. Long-acting dopamine receptor agonist cabergoline in early Parkinson’s disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs.18(11), 733–746 (2004).
   PubMed Web of Science ®Google Scholar
• Oertel WH, Wolters E, Sampaio C et al. Pergolide versus levodopa monotherapy in early Parkinson’s disease patients: The PELMOPET study. Mov. Disord. Published Online DOI: 10.1002/mds.20724 (2005)
   Google Scholar
• Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson’s disease: a 5-year follow-up. Neurology 37(5), 826–828 (1987).
   PubMed Web of Science ®Google Scholar
• Montastruc JL, Rascol O, Senard JM, Rascol A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson’s disease: a five year follow-up. J. Neurol. Neurosurg. Psych. 57(9), 1034–1038 (1994).
   PubMed Web of Science ®Google Scholar
• Kartzinel R, Teychenne P, Gillespie MM et al. Bromocriptine and levodopa (with or without carbidopa) in parkinsonism. Lancet 2(7980), 272–275 (1976).
   PubMedGoogle Scholar
• Lieberman AN, Kupersmith M, Gopinathan G, Estey E, Goodgold A, Goldstein M. Bromocriptine in Parkinson’s disease: further studies. Neurology 29(3), 363–369 (1979).
   PubMedGoogle Scholar
• McDonald RJ, Horowski R. Lisuride in the treatment of parkinsonism. Eur. Neurol. 22(4), 240–255 (1983).
   PubMedGoogle Scholar
• Olanow CW, Fahn S, Muenter M et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson’s disease. Mov. Disord. 9(1), 40–47 (1994).
   PubMed Web of Science ®Google Scholar
• Hutton JT, Morris JL, Brewer MA. Controlled study of the antiparkinsonian activity and tolerability of cabergoline. Neurology 43(3), 613–616 (1993).
   PubMedGoogle Scholar
• Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 49(1), 162–168 (1997).
   PubMed Web of Science ®Google Scholar
• Lieberman A, Olanow CW, Sethi K et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson’s disease. Ropinirole Study Group. Neurology. 51(4), 1057–1062 (1998).
   PubMed Web of Science ®Google Scholar
• Rascol O, Lees AJ, Senard JM et al. A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients. Adv. Neurol. 69, 531–534 (1996).
   PubMedGoogle Scholar
• Facca A, Sanchez-Ramos J. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias. Mov. Disord. 11(3), 327–329 (1996).
   PubMed Web of Science ®Google Scholar
• Cristina S, Zangaglia R, Mancini Fet al. High dose ropinirole in advanced Parkinson’s disease with severe dyskinesias. Clin. Neuropharm. 26(3), 146–150 (2003).
   PubMed Web of Science ®Google Scholar
• Rinne UK, Bracco F, Chouza C et al. Cabergoline in the treatment of early Parkinson’s disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology 48(2), 363–368. (1997).
   PubMed Web of Science ®Google Scholar
• Barone P, Bravi D, Bermejo-Pareja F et al. Pergolide monotherapy in the treatment of early Parkinson’s disease. A randomized controlled study. Neurology 53, 573–599 (1999).
   PubMed Web of Science ®Google Scholar
• Shannon KM, Bennett JP, Friedman JH for the Pramipexole Study Group. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. Neurology 49, 724–728 (1997).
   PubMed Web of Science ®Google Scholar
• Adler CH, Sethi KD, Hauser RA et al. Ropinirole for the treatment of early Parkinson’s disease. The Ropinirole Study Group. Neurology 49, 393–399 (1997).
   PubMed Web of Science ®Google Scholar
• Bonuccelli U. Comparing dopamine agonists in Parkinson’s disease. Curr. Opin. Neurology 16(Suppl. 1), S13–S19 (2003).
   PubMedGoogle Scholar
• Canesi M, Antonini A, Mariani CB et al. An overnight switch to ropinirole therapy in patients with Parkinson’s disease. J. Neural. Transm. 106, 925–929 (1999).
   PubMed Web of Science ®Google Scholar
• Ulm G, Schuler P, for the MODAC Study Group. Cabergoline versus Pergolide: a video-blinded, randomized, multicenter cross-over study. Akt. Neurol. 25, 360–365 (1999).
   Google Scholar
• Hanna PA, Ratkos L, Ondo WG, Jankovic J. Switching from pergolide to pramipexole in patients with Parkinson’s disease. J. Neural. Transm. 108, 63–70 (2001).
   PubMed Web of Science ®Google Scholar
• Grosset K, Needleman F, Macphee G, Grosset D. Switching from ergot to nonergot dopamine agonists in Parkinson’s disease: a clinical series and five-drug dose conversion table. Mov. Disord. 19(11), 1370–1374 (2004).
   PubMed Web of Science ®Google Scholar
• Goetz CG, Blasucci L, Stebbins GT. Switching dopamine agonists in advanced Parkinson’s disease. Is rapid titration preferable to slow? Neurology 52, 1227–1229 (1999).
   PubMed Web of Science ®Google Scholar
• Stocchi F, Vacca L, Berardelli A, Onofrj M, Manfredi M, Ruggieri S. Dual dopamine agonist treatment in Parkinson’s disease. J. Neurol. 250(7), 822–826 (2003).
   PubMedGoogle Scholar
• Factor SA. Intermittent subcutaneous apomorphine therapy in Parkinson’s disease. Neurology 62(Suppl. 4), 12–17 (2004).
   Google Scholar
• Colzi A, Turner K, Lees AJ. Continuous sc. waking day apomorphine in the long-term treatment of levodopa induced interdose dyskinesia in Parkinson’s disease. J. Neurol. Neurosur. Psych. 64, 573–576 (1998).
   PubMed Web of Science ®Google Scholar
• Katzenschlager R, Hughes A, Evans A et al. Continuous sc. apomorphine therapy improves dyskinesias in Parkinson’s disease: a prospective study using single-dose challenges. Mov. Disord. 20(2), 151–157 (2005)
   PubMed Web of Science ®Google Scholar
• Carter AJ, Muller RE. Pramipexole, a dopamine D2 autoreceptor agonist, decreases the extracellular concentration of dopamine in vivo. Eur. J. Pharmacol. 200(1), 65–72 (1991).
   PubMed Web of Science ®Google Scholar
• Fahn S. Welcome news about levodopa, but uncertainty remains. Ann. Neurol. 43(5), 551–554 (1998).
   PubMed Web of Science ®Google Scholar
• Murer MG, Dziewczapolski G, Menalled LB et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann. Neurol. 43(5), 561–575 (1998).
   PubMed Web of Science ®Google Scholar
• Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr. Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct. Science 294(5545), 1346–1349 (2001).
   PubMed Web of Science ®Google Scholar
• Fahn S, Oakes D, Shoulson I et al. Levodopa and the progression of Parkinson’s disease. N. Engl. J. Med.351(24), 2498–2508 (2004).
   PubMed Web of Science ®Google Scholar
• Ogawa N, Tanaka K, Asanuma M et al. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res. 657(1–2), 207–213 (1994).
   PubMed Web of Science ®Google Scholar
• Kondo T, Ito T, Sugita Y. Bromocriptine scavenges methamphetamine-induced hydroxyl radicals and attenuates dopamine depletion in mouse striatum. Ann. N. Y. Acad. Sci. 17(738), 222–229 (1994).
   Google Scholar
• Clow A, Freestone C, Lewis E, Dexter D, Sandler M, Glover V. The effect of pergolide and MDL 72974 on rat brain CuZn superoxide dismutase. Neurosci. Lett. 164(1–2), 41–43 (1993).
   PubMed Web of Science ®Google Scholar
• Gomez-Vargas M, Nishibayashi-Asanuma S, Asanuma M, Kondo Y, Iwata E, Ogawa N. Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain. Brain Res. 790(1–2), 202–208 (1998).
   PubMed Web of Science ®Google Scholar
• Nishibayashi S, Asanuma M, Kohno M, Gomez-Vargas M, Ogawa N. Scavenging effects of dopamine agonists on nitric oxide radicals. J. Neurochem. 67(5), 2208–2211 (1996).
   PubMed Web of Science ®Google Scholar
• Cassarino DS, Fall CP, Smith TS, Bennett JP Jr. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J. Neurochem. 71(1), 295–301 (1998).
   PubMed Web of Science ®Google Scholar
• Jenner P, Iravani MM, Haddon CO et al. Pramipexole protect against MPTP-induced dopaminergic cell loss in primates. Neurology 58, 496 (2002).
   Google Scholar
• Iida M, Miyazaki I, Tanaka K, Kabuto H, Iwata-Ichikawa E, Ogawa N. Dopamine D2 receptor-mediated anti-oxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res. 838(1–2), 51–59 (1999).
   PubMed Web of Science ®Google Scholar
• Olanow CW, Jenner P, Brooks D. Dopamine agonists and neuroprotection in Parkinson’s disease. Ann. Neurol. 44(3 Suppl. 1), S167–S174 (1998).
   PubMed Web of Science ®Google Scholar
• Finotti N, Castagna L, Moretti A, Marzatico F. Reduction of lipid peroxidation in different rat brain areas after cabergoline treatment. Pharmacol. Res. 42(4), 287–291 (2000).
   PubMed Web of Science ®Google Scholar
• Yoshioka M, Tanaka K, Miyazaki I et al. The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals. Neurosci. Res. 43(3), 259–567 (2002).
   PubMed Web of Science ®Google Scholar
• Anglade P, Vyas S, Javoy-Agid F et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson’s disease. Histol. Histopathol. 12(1), 25–31 (1997).
   PubMed Web of Science ®Google Scholar
• Tatton NA. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson’s disease. Exp. Neurol. 166(1), 29–43 (2000).
   PubMed Web of Science ®Google Scholar
• Hartmann A, Hirsch EC. Parkinson’s disease. The apoptosis hypothesis revisited. Adv. Neurol. 86, 143–153 (2001).
   PubMedGoogle Scholar
• Uberti D, Carsana T, Francisconi S, Toninelli GF, Canonico PL, Memo M. A novel mechanism for pergolide-induced neuroprotection: inhibition of NF-κB nuclear translocation. Biochem. Pharmacol. 67(9), 1743–1750 (2004).
   PubMedGoogle Scholar
• Gu M, Iravani MM, Cooper JM, King D, Jenner P, Schapira AH. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J. Neurochem. 91(5), 1075–1081 (2004).
   PubMed Web of Science ®Google Scholar
• Kitamura Y, Kosaka T, Kakimura JI et al. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. 54(6), 1046–1054 (1998).
   PubMed Web of Science ®Google Scholar
• Rodriguez MC, Obeso JA, Olanow CW. Subthalamic nucleus-mediated excitotoxicity in Parkinson’s disease: a target for neuroprotection. Ann. Neurol. 44(Suppl. 1), S175–S188 (1998).
   PubMed Web of Science ®Google Scholar
• Hurelbrink CB, Barker RA. Prospects for the treatment of Parkinson’s disease using neurotrophic factors. Expert. Opin. Pharmacother. 2(10), 1531–1543 (2001).
   PubMedGoogle Scholar
• Ohta M, Mizuta I, Ohta K, et al. Apomorphine upregulates NGF and GDNF synthesis in cultured mouse astrocytes. Biochem. Biophys. Res. Commun. 272(1), 18–22 (2000).
   PubMed Web of Science ®Google Scholar
• Ohta K, Kuno S, Mizuta I, Fujinami A, Matsui H, Ohta M. Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes. Life Sci. 73(5), 617–626 (2003).
   PubMed Web of Science ®Google Scholar
• Ohta K, Fujinami A, Kuno S et al. Cabergoline stimulates synthesis and secretion of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor by mouse astrocytes in primary culture. Pharmacology 71(3), 162–168 (2004).
   PubMed Web of Science ®Google Scholar
• Presgraves SP, Borwege S, Millan MJ, Joyce JN. Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells. Exp. Neurol. 190(1), 157–170 (2004).
   PubMed Web of Science ®Google Scholar
• Hoglinger GU, Rizk P, Muriel MP et al. Dopamine depletion impairs precursor cell proliferation in Parkinson’s disease. Nature Neurosci. 7(7), 726–735 (2004).
   PubMed Web of Science ®Google Scholar
• Brooks DJ. Imaging end points for monitoring neuroprotection in Parkinson’s disease. Ann. Neurol. 53(Suppl. 3), S110–S118 (2003).
   PubMedGoogle Scholar
• Rakshi JS, Pavese N, Uema T et al. A comparison of the progression of early Parkinson’s disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study. J. Neural. Transm. 109(12), 1433–1443 (2002).
   PubMed Web of Science ®Google Scholar
• Whone AL, Watts RL, Stoessl AJ et al. REAL-PET Study Group. Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Ann. Neurol. 54(1), 93–101 (2003).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson’s disease: a 4-year randomized controlled trial. Arch. Neurol. 61(6), 1044–1053 (2004).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson’s disease progression. JAMA287(13), 1653–1661 (2002).
   PubMed Web of Science ®Google Scholar
• Oertel WH, Schwarz J, Leenders KL et al. on behalf of the Pelmopet-Study Group. Results of a 3 year randomized, double-blind, PET-controlled study of Pergolide vs. L-dopa as monotherapy in early Parkinson’s disease (PELMOPET-trial). J. Neurol. Sci. 187(Suppl. 1), S444 (2001).
   Google Scholar
• Hobson DE, Lang AE, Martin WR et al. Excessive daytime sleepiness and sudden-onset sleep in Parkinson’s disease. A survey by the Canadian Movement Disorders Group. JAMA287, 455–463 (2002).
   PubMed Web of Science ®Google Scholar
• Arnulf I. Excessive daytime sleepiness in parkinsonism. Sleep. Med. Rev. 9,185–200 (2005).
   PubMed Web of Science ®Google Scholar
• Frucht SJ, Greene PE, Fahn S. Sleep episodes in Parkinson’s disease: a wake-up call. Mov. Disord. 15, 601–603 (2000).
   PubMedGoogle Scholar
• Frucht SJ, Rogers JD, Greene PE et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52, 1908–1910 (1999).
   PubMed Web of Science ®Google Scholar
• Cantor CR, Stern MB. Dopamine agonists and sleep in Parkinson’s disease. Neurology 58(Suppl. 1), S71–S78 (2002).
   PubMedGoogle Scholar
• Homann CN, Wenzel K, Suppan K et al. Sleep attacks in patients taking dopamine agonists: review. BMJ 324, 1483–1487 (2002).
   PubMed Web of Science ®Google Scholar
• Korner Y, Meindorfner C, Moller JC et al. Predictors of sudden onset of sleep in Parkinson’s disease. Mov. Disord. 19, 1298–1305 (2004).
   PubMed Web of Science ®Google Scholar
• Avorn J, Schneeweiss S, Sudarsky LR et al. Sudden uncontrollable somnolence and medication use in Parkinson’s disease. Arch. Neurol. 62, 1242–1248 (2005).
   PubMed Web of Science ®Google Scholar
• Hogl B, Saletu M, Brandauer E et al. Modafinil for the treatment of daytime sleepiness in Parkinson’s disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 25(8), 905–909 (2002).
   PubMed Web of Science ®Google Scholar
• Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease. Mov. Disord. 18(3), 287–293 (2003).
   PubMed Web of Science ®Google Scholar
• Muller T, Fritze J. Fibrosis associated with dopamine agonist therapy in Parkinson’s disease. Clin. Neuropharm. 26(3), 109–111 (2003).
   PubMed Web of Science ®Google Scholar
• McElvaney NG, Wilcox PG, Churg A et al. Pleuropulmonary disease during bromocriptine treatment of Parkinson’s disease. Arch. Intern. Med. 148, 2231–2236 (1988).
   Google Scholar
• Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE. Valvular heart disease in patients taking pergolide. Mayo Clin. Proc. 77(12), 1280–1286 (2002).
   Google Scholar
• Van Camp G, Flamez A, Cosyns B et al. Heart valvular disease in patients with Parkinson’s disease treated with high dose pergolide. Neurology 61, 859–861 (2003).
   PubMed Web of Science ®Google Scholar
• Foley P, Gerlach M, Double KL, Riederer P. Dopamine receptor agonists in the therapy of Parkinson’s disease. J. Neural Transm. 111(10–11), 1375–1446 (2004).
   Google Scholar